Bay 11-7821 (BAY 11-7082): Selective IKK Inhibitor for NF-κB Research

Executive Summary:
Bay 11-7821 (BAY 11-7082) is a selective IκB kinase (IKK) inhibitor with an IC50 of 10 μM, used extensively to block NF-κB pathway activation in cell-based and animal models (source: product_spec). It functions by suppressing TNFα-induced phosphorylation of IκB-α, thereby inhibiting pro-inflammatory gene expression (source: paper). Bay 11-7821 also induces apoptosis in B-cell lymphoma and leukemic T cells, and suppresses NALP3 inflammasome activation in macrophages (source: internal_article). In vivo, it suppresses tumor growth in mouse xenograft models of gastric cancer. Its solubility profile and storage requirements are critical for experimental reproducibility (source: product_spec).

Biological Rationale

The NF-κB signaling pathway coordinates immune and inflammatory responses. Aberrant NF-κB activation is implicated in chronic inflammation and cancer. IκB kinase (IKK) phosphorylates IκB-α, leading to its degradation and subsequent NF-κB translocation to the nucleus. Pharmacological inhibition of IKK is a validated strategy to dissect the contributions of NF-κB to inflammatory signaling and apoptosis regulation (source: internal_article). Bay 11-7821 is widely used for these purposes, offering mechanistic precision in both cancer research and studies of inflammatory disease models.

Mechanism of Action of Bay 11-7821 (BAY 11-7082)

• IKK Inhibition: Bay 11-7821 irreversibly inhibits IκB kinase, blocking phosphorylation of IκB-α (IC50: 10 μM) (source: product_spec).
• NF-κB Pathway Blockade: Suppresses TNFα-mediated activation of NF-κB and downstream expression of adhesion molecules such as E-selectin, VCAM-1, and ICAM-1 (source: paper).
• Inflammasome Modulation: Inhibits NALP3 inflammasome activation in macrophages, reducing secretion of pro-inflammatory cytokines (source: internal_article).
• Apoptosis Induction: Triggers apoptosis in B-cell lymphoma and leukemic T cells, supporting utility in apoptosis regulation study (source: internal_article).
• E2 Ubiquitin Conjugating Enzyme Inhibition: Bay 11-7821 also inhibits E2 enzyme activity, contributing to its anti-inflammatory effects (workflow_recommendation).

Evidence & Benchmarks

• Bay 11-7821 inhibits IKK activity with an IC50 of 10 μM in cell-free assays (source: product_spec).
• Suppresses TNFα-induced phosphorylation of IκB-α and blocks NF-κB luciferase reporter activity in cell-based assays (source: paper).
• Demonstrates antiproliferative effects in non-small cell lung cancer NCI-H1703 cells at concentrations up to 8 μM (source: product_spec).
• In vivo, intratumoral injection in mice xenografted with human gastric cancer HGC27 cells suppresses tumor growth and induces apoptosis in a dose-dependent manner (source: product_spec).
• Reduces NALP3 inflammasome activation and IL-1β secretion in macrophage cultures (source: internal_article).
• Bay 11-7821 is insoluble in water but soluble at ≥64 mg/mL in DMSO and ≥10.64 mg/mL in ethanol with gentle warming and ultrasonication (source: product_spec).

This article extends the mechanistic details found in "Bay 11-7821 (BAY 11-7082): Advanced Insights into NF-κB Pathway Inhibition" by providing updated solubility parameters and in vivo benchmarks not covered in prior reviews.

Applications, Limits & Misconceptions

• Inflammatory Signaling Pathway Research: Bay 11-7821 is used to dissect the role of IKK/NF-κB in macrophage activation, cytokine production, and endothelial permeability (source: paper).
• Apoptosis Regulation Study: Enables precise induction and measurement of apoptosis in hematologic malignancy models (source: internal_article).
• Cancer Research: Validated in xenograft models for studying tumor growth suppression and apoptosis induction (source: product_spec).
• B-cell Lymphoma Research: Used to probe NF-κB dependence in lymphoma cell survival (source: internal_article).

Common Pitfalls or Misconceptions

• Bay 11-7821 is not suitable for long-term solution storage due to instability; fresh preparation is recommended (source: product_spec).
• It is insoluble in water; DMSO or ethanol (with ultrasonication) are required for effective solubilization (source: product_spec).
• Not all observed cellular effects are solely due to IKK inhibition; off-target effects, such as E2 ubiquitin conjugating enzyme inhibition, should be considered (workflow_recommendation).
• Bay 11-7821 is not a clinical therapeutic; it is strictly for research use (source: product_spec).
• High concentrations may induce cytotoxicity unrelated to NF-κB inhibition; dose-dependent controls are essential (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• IKK in vitro inhibition assay | IC50: 10 μM | Cell-free and cell-based assays | Standard for IKK inhibitor benchmarking | product_spec
• NF-κB luciferase reporter assay | 2–8 μM | Cell-based (e.g., NCI-H1703) | Dose-dependent inhibition observed | product_spec
• Macrophage inflammasome assay | 5–10 μM | Mouse macrophages; IL-1β readout | Suppresses NALP3 activation | internal_article
• Solubility (DMSO) | ≥64 mg/mL | Solution preparation | Enables high-concentration stock solutions | product_spec
• Solubility (ethanol, warmed/ultrasonicated) | ≥10.64 mg/mL | Alternate solvent | For ethanol-based workflows | product_spec
• Storage temperature | -20°C | Solid compound | Maintains stability prior to use | product_spec
• Solution stability | Not recommended for long-term storage | Fresh solution only | Prevents degradation artifacts | product_spec

For detailed integration into workflows targeting inflammatory signaling or apoptosis regulation, see "Bay 11-7821: Precision IKK Inhibition for NF-κB Pathway Research", which this article updates with clarified solubility and storage recommendations.

Conclusion & Outlook

Bay 11-7821 (BAY 11-7082), distributed by APExBIO, is a selective IKK inhibitor that enables precise modulation of NF-κB signaling and apoptosis in research models (source: product_spec). Its well-characterized mechanism and robust in vitro and in vivo activity make it a valuable tool for inflammation and cancer biology workflows. Limitations include solubility constraints and potential off-target effects at high concentrations. Future studies should continue to refine its application window and distinguish IKK-specific from pleiotropic effects (source: paper). For further mechanistic insights and translational developments, see "Bay 11-7821 (BAY 11-7082): Advancing Inflammatory Pathway Research", which this article extends by focusing on in vivo and workflow integration benchmarks.

For ordering and detailed protocols, refer to the Bay 11-7821 (BAY 11-7082) product page (SKU: A4210).